nach oben

Tumor Biology

Erschienen in:

22.07.2016 | Original Article

4.1N is involved in a flotillin-1/β-catenin/Wnt pathway and suppresses cell proliferation and migration in non-small cell lung cancer cell lines

verfasst von: Qin Yang, Min Zhu, Zi Wang, Hui Li, Weihua Zhou, Xiaojuan Xiao, Bin Zhang, Weixin Hu, Jing Liu

Erschienen in: Tumor Biology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

The membrane-cytoskeletal protein 4.1N has recently been proposed as a tumor suppressor in a number of cancers of epithelial origin, including non-small-cell lung cancer (NSCLC). However, the molecular mechanism associated with 4.1N tumor suppression remains has not been thoroughly characterized. In this study, 4.1N was shown to directly interact with the lipid raft marker flotillin-1 through its FERM and U2 domains in several different NSCLC cell lines using immunoprecipitation, co-immunoprecipitation and pull-down assays. Moreover, 4.1N silencing/overexpression experiments in paired 95C/95D cells that are of homologous origin but varying endogenous 4.1N expression (high expression in 95C cells, low expression in 95D cells) indicated that 4.1N is involved in the suppression of cell proliferation and migration through a flotillin-1/β-catenin/Wnt pathway. Taken together, the findings of this study help to elucidate the novel tumor suppressor role of 4.1N in NSCLC.

Siegel R, Naishadham D, Jemal A, Cancer statistics. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138. CrossRefPubMed

Guo P, Huang ZL, Yu P, Li K. Trends in cancer mortality in China: an update. Ann Oncol. 2012;23(10):2755–62. doi:10.1093/annonc/mds069. CrossRefPubMed

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. doi:10.4065/83.5.584. CrossRefPubMedPubMedCentral

Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(Suppl 1):5–13. doi:10.1634/theoncologist.13-S1-5. CrossRefPubMed

Diakowski W, Grzybek M, Sikorski AF. Protein 4.1, a component of the erythrocyte membrane skeleton and its related homologue proteins forming the protein 4.1/FERM superfamily. Folia Histochem Cytobiol. 2006;44(4):231–48.PubMed

Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999;59(1):35–43.PubMed

Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 2000;9(10):1495–500.CrossRefPubMed

Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. Neurobiol Dis. 2003;13(3):191–202.CrossRefPubMed

Wang Z, Zhang J, Ye M, Zhu M, Zhang B, Roy M, et al. Tumor suppressor role of protein 4.1B/DAL-1. Cell Mol Life Sci. 2014;71(24):4815–30. doi:10.1007/s00018-014-1707-z. CrossRefPubMed

10.

Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci. 2002;115(Pt 21):3991–4000.CrossRefPubMed

11.

Kittiniyom K, Gorse KM, Dalbegue F, Lichy JH, Taubenberger JK, Newsham IF. Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res 2001;3(3):192–198.

12.

Ohno N, Terada N, Murata S, Yamakawa H, Newsham IF, Katoh R, et al. Immunolocalization of protein 4.1B/DAL-1 during neoplastic transformation of mouse and human intestinal epithelium. Histochem Cell Biol. 2004;122(6):579–86. doi:10.1007/s00418-004-0716-7. CrossRefPubMed

13.

Terada N, Ohno N, Yamakawa H, Baba T, Fujii Y, Christofori G, et al. Protein 4.1B in mouse islets of Langerhans and beta-cell tumorigenesis. Histochem Cell Biol. 2003;120(4):277–83. doi:10.1007/s00418-003-0573-9. CrossRefPubMed

14.

Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer. 2002;100(2):181–8. doi:10.1002/ijc.10470. CrossRefPubMed

15.

Wang Z, Zhang J, Zeng Y, Sun S, Zhang J, Zhang B, Zhu M, Ouyang R, Ma B, Ye M, An X, Liu J. Knockout of 4.1B triggers malignant transformation in SV40T-immortalized mouse embryo fibroblast cells. Mol Carcinog. 2016; doi:10.1002/mc.22515.

16.

Xi CG, Ren CX, Hu A, Lin J, Yao Q, Wang Y, et al. Defective expression of protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer. Gynecol Oncol. 2013;131(3):764–71. doi:10.1016/j.ygyno.2013.08.015.CrossRefPubMed

17.

Ji ZY, Shi XF, Liu X, Shi Y, Zhou QQ, Liu XL, et al. The membrane-cytoskeletal protein 4.1N is involved in the process of cell adhesion, migration and invasion of breast cancer cells. Exp Ther Med. 2012;4(4):736–40. doi:10.3892/Etm.2012.653.PubMedPubMedCentral

18.

Ye K, Compton DA, Lai MM, Walensky LD, Snyder SH. Protein 4.1N binding to nuclear mitotic apparatus protein in PC12 cells mediates the antiproliferative actions of nerve growth factor. J Neurosci. 1999;19(24):10747–56.PubMed

19.

Wang Z, Ma B, Li H, Xiao X, Zhou W, Liu F, et al. Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC. Oncotarget. 2016;7(1):509–23. doi:10.18632/oncotarget.6312.PubMed

20.

Han BG, Nunomura W, Takakuwa Y, Mohandas N, Jap BK. Protein 4.1R core domain structure and insights into regulation of cytoskeletal organization. Nat Struct Biol. 2000;7(10):871–5. doi:10.1038/82819. CrossRefPubMed

21.

Zhou Y, Du G, Hu X, Yu S, Liu Y, Xu Y, et al. Nectin-like molecule 1 is a protein 4.1N associated protein and recruits protein 4.1N from cytoplasm to the plasma membrane. Biochim Biophys Acta. 2005;1669(2):142–54. doi:10.1016/j.bbamem.2005.01.013. CrossRefPubMed

22.

Loscher W, Puskarjov M, Kaila K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology. 2013;69:62–74. doi:10.1016/j.neuropharm.2012.05.045. CrossRefPubMed

23.

Gimm JA, An X, Nunomura W, Mohandas N. Functional characterization of spectrin-actin-binding domains in 4.1 family of proteins. Biochemistry. 2002;41(23):7275–82.CrossRefPubMed

24.

Baines AJ. The spectrin-ankyrin-4.1-adducin membrane skeleton: adapting eukaryotic cells to the demands of animal life. Protoplasma. 2010;244(1–4):99–131. doi:10.1007/s00709-010-0181-1. CrossRefPubMed

25.

Banning A, Kurrle N, Meister M, Tikkanen R. Flotillins in receptor tyrosine kinase signaling and cancer. Cells. 2014;3(1):129–49. doi:10.3390/cells3010129. CrossRefPubMedPubMedCentral

26.

Rivera-Milla E, Stuermer CA, Malaga-Trillo E. Ancient origin of reggie (flotillin), reggie-like, and other lipid-raft proteins: convergent evolution of the SPFH domain. Cell Mol Life Sci. 2006;63(3):343–57. doi:10.1007/s00018-005-5434-3. CrossRefPubMed

27.

Browman DT, Hoegg MB, Robbins SM. The SPFH domain-containing proteins: more than lipid raft markers. Trends Cell Biol. 2007;17(8):394–402. doi:10.1016/j.tcb.2007.06.005. CrossRefPubMed

28.

Stuermer CA. The reggie/flotillin connection to growth. Trends Cell Biol. 2010;20(1):6–13. doi:10.1016/j.tcb.2009.10.003. CrossRefPubMed

29.

Edgar AJ, Polak JM. Flotillin-1: gene structure: cDNA cloning from human lung and the identification of alternative polyadenylation signals. Int J Biochem Cell Biol. 2001;33(1):53–64.CrossRefPubMed

30.

Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol. 2006;8(1):46–54. doi:10.1038/ncb1342. CrossRefPubMed

31.

Li L, Luo J, Wang B, Wang D, Xie X, Yuan L et al. Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer 2013;12:163. doi:10.1186/1476-4598-12-163.

32.

Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, et al. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 2011;17(10):3089–99. doi:10.1158/1078-0432.CCR-10-3068. CrossRefPubMed

33.

Zhang SH, Wang CJ, Shi L, Li XH, Zhou J, Song LB, et al. High expression of FLOT1 is associated with progression and poor prognosis in hepatocellular carcinoma. PLoS One. 2013;8(6):e64709. doi:10.1371/journal.pone.0064709. CrossRefPubMedPubMedCentral

34.

Song L, Gong H, Lin C, Wang C, Liu L, Wu J, et al. Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology. 2012;143(4):995–1005.e12. doi:10.1053/j.gastro.2012.06.033.CrossRefPubMed

35.

Li H, Wang RM, Liu SG, Zhang JP, Luo JY, Zhang BJ, et al. Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancer. Tumour Biol: J Int Soc Oncodevel Biol Med. 2014;35(4):3311–5. doi:10.1007/s13277-013-1434-3. CrossRef

36.

Zhang PF, Zeng GQ, Hu R, Li C, Yi H, Li MY, et al. Identification of flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis. J Proteome. 2012;77:202–14. doi:10.1016/j.jprot.r2012.08.021.CrossRef

37.

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002;111(2):241–50.CrossRefPubMed

38.

Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 2009;28(21):2163–72. doi:10.1038/onc.2009.82. CrossRefPubMedPubMedCentral

39.

Zhang QQ, Zhou DL, Lei Y, Zheng L, Chen SX, Gou HJ, et al. Slit2/Robo1 signaling promotes intestinal tumorigenesis through Src-mediated activation of the Wnt/beta-catenin pathway. Oncotarget. 2015;6(5):3123–35.CrossRefPubMed

40.

Hu Z, Xie L. LHX6 inhibits breast cancer cell proliferation and invasion via repression of the Wnt/betacatenin signaling pathway. Mol Med Rep. 2015. doi:10.3892/mmr.2015.3997.

41.

You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, et al. Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol. 2002;157(3):429–40. doi:10.1083/jcb.200201110. CrossRefPubMedPubMedCentral

42.

Kato N, Nakanishi M, Hirashima N. Flotillin-1 regulates IgE receptor-mediated signaling in rat basophilic leukemia (RBL-2H3) cells. J Immunol. 2006;177(1):147–54.CrossRefPubMed

43.

Kioka N, Ueda K, Amachi T. Vinexin, CAP/ponsin, ArgBP2: a novel adaptor protein family regulating cytoskeletal organization and signal transduction. Cell Struct Funct. 2002;27(1):1–7.CrossRefPubMed

44.

Liu J, Deyoung SM, Zhang M, Dold LH, Saltiel AR. The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes. J Biol Chem. 2005;280(16):16125–34. doi:10.1074/jbc.M500940200. CrossRefPubMed

45.

Solis GP, Schrock Y, Hulsbusch N, Wiechers M, Plattner H, Stuermer CA. Reggies/flotillins regulate E-cadherin-mediated cell contact formation by affecting EGFR trafficking. Mol Biol Cell. 2012;23(10):1812–25. doi:10.1091/mbc.E11-12-1006. CrossRefPubMedPubMedCentral

46.

Kajla S, Mondol AS, Nagasawa A, Zhang Y, Kato M, Matsuno K, et al. A crucial role for Nox 1 in redox-dependent regulation of Wnt-beta-catenin signaling. FASEB J: Off Publ Fed Am Soc Exp Biol. 2012;26(5):2049–59. doi:10.1096/fj.11-196360. CrossRef

47.

Yokoyama N, Malbon CC. Dishevelled-2 docks and activates Src in a Wnt-dependent manner. J Cell Sci. 2009;122(Pt 24):4439–51. doi:10.1242/jcs.051847. CrossRefPubMedPubMedCentral

48.

Wang H, Liu C, Debnath G, Baines AJ, Conboy JG, Mohandas N, et al. Comprehensive characterization of expression patterns of protein 4.1 family members in mouse adrenal gland: implications for functions. Histochem Cell Biol. 2010;134(4):411–20. doi:10.1007/s00418-010-0749-z. CrossRefPubMed

49.

Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.CrossRefPubMed

50.

Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843–50. doi:10.1038/nature03319. CrossRefPubMed

51.

Harland R, Gerhart J. Formation and function of Spemann’s organizer. Annu Rev Cell Dev Biol. 1997;13:611–67. doi:10.1146/annurev.cellbio.13.1.611. CrossRefPubMed

52.

Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH. Membrane localization of the U2 domain of protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene. 2005;24(11):1946–57. doi:10.1038/sj.onc.1208335. CrossRefPubMed

53.

Thorn CC, Freeman TC, Scott N, Guillou PJ, Jayne DG. Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut. 2009;58(3):404–12. doi:10.1136/gut.2008.157255. CrossRefPubMed

54.

Vlaeminck-Guillem V, Gillet G, Rimokh R. SRC: marker or actor in prostate cancer aggressiveness. Front Oncol. 2014;4:222. doi:10.3389/fonc.2014.00222.CrossRefPubMedPubMedCentral

55.

Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A, et al. p120 catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin interaction. Mol Cell Biol. 2003;23(7):2287–97.CrossRefPubMedPubMedCentral

56.

Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem. 1999;274(51):36734–40.CrossRefPubMed

57.

Le TL, Yap AS, Stow JL. Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J Cell Biol. 1999;146(1):219–32.CrossRefPubMedPubMedCentral

58.

Karni R, Gus Y, Dor Y, Meyuhas O, Levitzki A. Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol. 2005;25(12):5031–9. doi:10.1128/MCB.25.12.5031-5039.2005. CrossRefPubMedPubMedCentral

Titel: 4.1N is involved in a flotillin-1/β-catenin/Wnt pathway and suppresses cell proliferation and migration in non-small cell lung cancer cell lines
verfasst von: Qin Yang
Min Zhu
Zi Wang
Hui Li
Weihua Zhou
Xiaojuan Xiao
Bin Zhang
Weixin Hu
Jing Liu
Publikationsdatum: 22.07.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 9/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5146-3

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

4.1N is involved in a flotillin-1/β-catenin/Wnt pathway and suppresses cell proliferation and migration in non-small cell lung cancer cell lines

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer

Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation

Overexpression of MYCN promotes proliferation of non-small cell lung cancer

Emerging targets for radioprotection and radiosensitization in radiotherapy

Silencing of TGIF attenuates the tumorigenicity of A549 cells in vitro and in vivo

MicroRNA-125b promotes invasion and metastasis of gastric cancer by targeting STARD13 and NEU1

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie